T
The startup develops ophthalmic drug candidates specifically targeting glaucoma, utilizing advanced medication delivery systems to enhance patient safety and adherence. Their approach aims to transform established eye medications into effective therapies, paving the way for future applications across various ocular conditions.
Updated 3 months ago
Funding
$43.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops ophthalmic drug candidates specifically targeting glaucoma, utilizing advanced medication delivery systems to enhance patient safety and adherence. Their approach aims to transform established eye medications into effective therapies, paving the way for future applications across various ocular conditions.